https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-metastatic-melanoma-likelihood-of-approval/
Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Metastatic Melanoma.
metastatic melanomaabexinostatpharmaceuticalslikelihoodapproval